VXA-G2.4-NS
Sponsors
Vaxart
Conditions
Norovirus InfectionNorovirus Infections
Phase 1
Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines
CompletedNCT03897309
Start: 2019-03-20End: 2021-04-01Updated: 2022-09-21
A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old
CompletedNCT06944717
Start: 2025-03-03End: 2026-04-14Updated: 2026-07-27
A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants
CompletedNCT07254728
Start: 2023-10-27End: 2024-12-13Updated: 2026-04-15